Adverum Biotechnologies Inc.

1.51-0.0300-1.95%Vol 388.06K1Y Perf -37.40%
Aug 11th, 2022 16:00 DELAYED
BID1.45 ASK1.64
Open1.53 Previous Close1.54
Pre-Market- After-Market1.49
 - -  -0.02 -1.32%
Target Price
3.50 
Analyst Rating
Moderate Buy 1.67
Potential %
131.79 
Finscreener Ranking
★★★+     50.95
Insiders Trans % 3/6/12 mo.
100/100/67 
Value Ranking
★★★+     53.72
Insiders Value % 3/6/12 mo.
100/100/10 
Growth Ranking
★+     43.35
Insiders Shares Cnt. % 3/6/12 mo.
100/100/46 
Income Ranking
 —    -
Price Range Ratio 52W %
40.27 
Earnings Rating
Sell
Market Cap149.14M 
Earnings Date
11th Aug 2022
Alpha0.02 Standard Deviation0.29
Beta1.00 

Today's Price Range

1.491.59

52W Range

0.79542.57

5 Year PE Ratio Range

-7.30-1.30

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-6.21%
1 Month
-13.22%
3 Months
66.17%
6 Months
6.34%
1 Year
-37.40%
3 Years
-86.85%
5 Years
-40.78%
10 Years
-

TickerPriceChg.Chg.%
ADVM1.51-0.0300-1.95
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-
-1 948.30
-1 886.40
-13 415.90
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-48.48
-27.54
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.34-0.38-11.76
Q04 2021-0.42-0.3516.67
Q03 2021-0.42-0.397.14
Q02 2021-0.37-0.45-21.62
Q01 2021-0.38-0.2923.68
Q04 2020-0.32-0.39-21.88
Q03 2020-0.35-0.3111.43
Q02 2020-0.30-0.36-20.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.38-5.56Negative
9/2022 QR-0.38-2.70Negative
12/2022 FY-1.56-4.70Negative
12/2023 FY-1.350.00-
Next Report Date-
Estimated EPS Next Report-0.38
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume388.06K
Shares Outstanding98.77K
Shares Float86.79M
Trades Count2.35K
Dollar Volume594.40K
Avg. Volume807.67K
Avg. Weekly Volume345.99K
Avg. Monthly Volume842.39K
Avg. Quarterly Volume1.23M

Adverum Biotechnologies Inc. (NASDAQ: ADVM) stock closed at 1.51 per share at the end of the most recent trading day (a -1.95% change compared to the prior day closing price) with a volume of 388.06K shares and market capitalization of 149.14M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 114 people. Adverum Biotechnologies Inc. CEO is Laurent Fischer.

The one-year performance of Adverum Biotechnologies Inc. stock is -37.4%, while year-to-date (YTD) performance is -14.2%. ADVM stock has a five-year performance of -40.78%. Its 52-week range is between 0.79535 and 2.57, which gives ADVM stock a 52-week price range ratio of 40.27%

Adverum Biotechnologies Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.58, a price-to-sale (PS) ratio of 18.06, a price to cashflow ratio of 242.90, a PEG ratio of 2.32, a ROA of -36.77%, a ROC of -37.33% and a ROE of -45.95%. The company’s profit margin is -%, its EBITDA margin is -1 886.40%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Adverum Biotechnologies Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.38 for the next earnings report. Adverum Biotechnologies Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Adverum Biotechnologies Inc. is Moderate Buy (1.67), with a target price of $3.5, which is +131.79% compared to the current price. The earnings rating for Adverum Biotechnologies Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adverum Biotechnologies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adverum Biotechnologies Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.67, ATR14 : 0.13, CCI20 : -33.61, Chaikin Money Flow : -0.02, MACD : 0.04, Money Flow Index : 37.91, ROC : -0.65, RSI : 38.61, STOCH (14,3) : 60.00, STOCH RSI : 0.94, UO : 56.47, Williams %R : -40.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adverum Biotechnologies Inc. in the last 12-months were: Dawn A. Svoronos (Buy at a value of $25 578), James Scopa (Sold 50 000 shares of value $109 000 ), Julie Clark (Sold 4 766 shares of value $10 342 ), Kishor Peter Soparkar (Buy at a value of $24 994), Laurent Fischer (Buy at a value of $27 800), Peter Soparkar (Buy at a value of $24 994), Richard Beckman (Buy at a value of $8 228), Rupert D¿Souza (Buy at a value of $16 857), Setareh Seyedkazemi (Buy at a value of $16 800)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
1 (33.33 %)
1 (33.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
2 (66.67 %)
2 (66.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
2.33
Moderate Buy
2.33

Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. The company is committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye, who currently have limited or burdensome treatment options. Its services are focused on advancing three lead gene therapy programs to address unmet needs in wet age-related macular degeneration and in rare diseases alpha-1 antitrypsin deficiency and hereditary angioedema. Its leading programs include ADVM-022, ADVM-043 and ADVM-053.

CEO: Laurent Fischer

Telephone: +1 650 659-9323

Address: 800 Saginaw Drive, Redwood CIty 94063, CA, US

Number of employees: 114

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

73%27%

Bearish Bullish

76%24%

Bearish Bullish

65%35%

TipRanks News for ADVM

Sun, 08 May 2022 16:55 GMT Adverum Biotechnologies (ADVM) Receives a Hold from Chardan Capital

- TipRanks. All rights reserved.

News

Stocktwits